512 related articles for article (PubMed ID: 22890223)
1. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Price S; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2012 Sep; 107(9):1409-22. PubMed ID: 22890223
[TBL] [Abstract][Full Text] [Related]
2. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
[TBL] [Abstract][Full Text] [Related]
3. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
[TBL] [Abstract][Full Text] [Related]
4. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
D'Haens G; Reinisch W; Colombel JF; Panes J; Ghosh S; Prantera C; Lindgren S; Hommes DW; Huang Z; Boice J; Huyck S; Cornillie F;
J Crohns Colitis; 2017 Jun; 11(6):680-689. PubMed ID: 28025307
[TBL] [Abstract][Full Text] [Related]
5. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
Lichtenstein GR; Rutgeerts P; Sandborn WJ; Sands BE; Diamond RH; Blank M; Montello J; Tang L; Cornillie F; Colombel JF
Am J Gastroenterol; 2012 Jul; 107(7):1051-63. PubMed ID: 22613901
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Safdi M; Popp JW; Langholff W; Sandborn WJ
Inflamm Bowel Dis; 2018 Feb; 24(3):490-501. PubMed ID: 29462395
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
[TBL] [Abstract][Full Text] [Related]
9. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
10. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
11. What to take from TREAT?
Hanauer SB
Am J Gastroenterol; 2012 Sep; 107(9):1423-5. PubMed ID: 22951879
[TBL] [Abstract][Full Text] [Related]
12. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
13. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Marehbian J; Arrighi HM; Hass S; Tian H; Sandborn WJ
Am J Gastroenterol; 2009 Oct; 104(10):2524-33. PubMed ID: 19532125
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
15. Safety of infliximab in Crohn's disease: a large single-center experience.
Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ
Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]